UBS AM
NERV icon

UBS AM’s Minerva Neurosciences NERV Stock Holding History

UBS AM’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,608
Closed -$286K – 2733
2019
Q3 		$286K Buy
4,608
+1,308
+40% +$74.1K ﹤0.01% 2473
2019
Q2 		$149K Hold
3,300
– – ﹤0.01% 2605
2019
Q1 		$208K Hold
3,300
– – ﹤0.01% 2440
2018
Q4 		$178K Hold
3,300
– – ﹤0.01% 2421
2018
Q3 		$331K Hold
3,300
– – ﹤0.01% 2242
2018
Q2 		$218K Hold
3,300
– – ﹤0.01% 2444
2018
Q1 		$165K Buy
3,300
+762
+30% +$36.6K ﹤0.01% 2415
2017
Q4 		$123K Hold
2,538
– – ﹤0.01% 2382
2017
Q3 		$154K Buy
+2,538
New +$146K ﹤0.01% 2315

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
IVAI
Index Venture Associates IV St. Helier, Channel Islands, Jersey $6.24M AUM
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

UBS AM's NERV Position: Q4 2019 in Review

UBS AM sold out of Minerva Neurosciences (NERV) in Q4 2019, closing a stake of 4,608 shares — an estimated $286K sold.

UBS AM first reported a position in NERV in Q3 2017 and held it in 9 quarters. The position peaked at $331K in Q3 2018. 92 funds tracked by Wall St. Rank hold NERV as of Q4 2019.

  • UBS AM reported no remaining Minerva Neurosciences position as of Q4 2019 after selling out during the quarter.
  • UBS AM sold 4,608 Minerva Neurosciences shares in Q4 2019, an estimated $286K.
  • UBS AM first reported a position in Minerva Neurosciences in Q3 2017 and held it in 9 quarters.
  • UBS AM's Minerva Neurosciences position peaked at $331K in Q3 2018.
  • 92 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2019.

Based on UBS AM's 13F filing for Q4 2019, filed 14 Feb 2020.